Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III
- Akiyoshi Miyazawa; Junya Ako; Yoichiro Hongo; Seung-Ho Hur; Ichizo Tsujino; Brian K. Courtney; Ali H.M. Hassan; David E. Kandzari; Yasuhiro Honda; Peter J. Fitzgerald
- Dept. of Internal Medicine (내과학)
- Issue Date
- American Heart Journal, Vol.155(1) : 108-113, 2008
- Background The purpose of this study was to investigate the vascular response of zotarolimus-eluting stent (ZES)
and sirolimus-eluting stent (SES) using serial intravascular ultrasound (IVUS).
Methods Data were obtained from the Endeavor Drug-Eluting Coronary Stent System Versus the Center Siromlimus-
Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR) III trial, a randomized study
comparing ZES and SES for the treatment of de novo native coronary artery lesions. Serial (baseline and 8-month follow-up)
IVUS was available in 258 patients (190 ZES, 68 SES).
Results At 8 months, ZES had greater percentage of neointimal volume index (ZES 1.1 ± 0.8 mm3/mm vs SES 0.2 ±
0.1 mm3/mm, P b .01), resulting in smaller lumen volume index (6.0 ± 2.0 mm3/mm vs 7.0 ± 2.1 mm3/mm, P b .05).
Zotarolimus-eluting stents showed larger IVUS-detectable neointimal coverage over stent surface (50.2% vs 10.5%, P b .01)
and greater mean neointimal thickness (0.19 ± 0.07 mm vs 0.10 ± 0.06 mm, P b .01). Zotarolimus-eluting stents had a
significantly lower incidence of late-acquired incomplete stent apposition.
Conclusions Zotarolimus-eluting stent is associated with a significantly greater amount of neointimal hyperplasia
compared with SES. This amount of hyperplasia in ZES is distributed throughout the stent at 8-month follow-up. (Am Heart J
- Appears in Collections:
- 1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
- Keimyung Author(s)
- Full Text
- File in this Item
- RIS (EndNote)
- XLS (Excel)